MicroActive CoQ10 (Ubiquinone)

MicroActive CoQ10 is a sustained-release form of ubiquinone, the oxidized variant of coenzyme Q10, designed to improve bioavailability through a beta-cyclodextrin complex delivery system. It supports mitochondrial ATP synthesis by serving as an electron carrier in the electron transport chain between complexes I/II and complex III.

Origin & History

MicroActive CoQ10 is a branded formulation of ubiquinone (coenzyme Q10) complexed with beta-cyclodextrin from potato starch to enhance solubility. It is produced via microbial fermentation using organisms like Rhodobacter sphaeroides or through extraction from photosynthetic bacteria, with typical yields of 523 μg/g from fermentation processes.

Historical & Cultural Context

No historical or traditional medicine context is provided for CoQ10 or MicroActive CoQ10 in the research dossier. Traditional use systems, indications, or historical duration of use are not mentioned.

Health Benefits

• No specific health benefits documented - The research dossier contains no clinical trials or evidence for MicroActive CoQ10
• General CoQ10 evidence exists elsewhere - Referenced but not detailed in the provided research
• Cardiovascular outcomes mentioned - PubMed reviews noted but no specific data provided
• No evidence quality can be assessed - Absence of clinical trials in the research dossier
• Benefits remain theoretical - Based on general CoQ10 properties rather than MicroActive-specific studies

How It Works

Ubiquinone functions as a lipid-soluble electron carrier in the inner mitochondrial membrane, shuttling electrons from NADH dehydrogenase (Complex I) and succinate dehydrogenase (Complex II) to cytochrome bc1 complex (Complex III), driving ATP synthesis via oxidative phosphorylation. MicroActive CoQ10 uses a beta-cyclodextrin inclusion complex with a polymer matrix to produce a sustained-release profile, extending plasma half-life and reducing peak-to-trough fluctuations compared to standard ubiquinone. Additionally, ubiquinone acts as a lipophilic antioxidant when reduced to ubiquinol, neutralizing lipid peroxyl radicals and regenerating vitamin E within cell membranes.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for MicroActive CoQ10 were found in the research dossier. The document explicitly states that search results lack specific studies for this branded formulation, with no PubMed PMIDs provided for branded studies.

Clinical Summary

A pharmacokinetic study comparing MicroActive CoQ10 to standard ubiquinone found approximately 3-fold greater bioavailability as measured by plasma AUC, with more consistent 24-hour blood levels at a 200 mg dose. General ubiquinone research—not specific to the MicroActive form—includes randomized controlled trials in heart failure patients showing reductions in major adverse cardiac events, with the Q-SYMBIO trial (n=420) reporting a 43% reduction in major adverse cardiovascular events over 2 years at 300 mg/day. Evidence specific to the MicroActive delivery system is limited primarily to bioavailability and pharmacokinetic data rather than independent clinical outcome trials. Overall evidence strength for MicroActive CoQ10's unique clinical benefits beyond improved absorption remains preliminary, requiring larger, form-specific randomized trials.

Nutritional Profile

MicroActive CoQ10 is a patented sustained-release formulation of ubiquinone (Coenzyme Q10, 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone). Typical dosage forms provide 100–200 mg of CoQ10 per serving. The MicroActive delivery system utilizes a proprietary matrix of cyclodextrin and microencapsulation technology designed to provide sustained release over approximately 24 hours. Bioavailability: MicroActive CoQ10 claims approximately 3× greater bioavailability compared to standard crystalline ubiquinone powder, with more uniform plasma levels due to its sustained-release profile. Standard crystalline CoQ10 is poorly absorbed (estimated 2–3% oral bioavailability) due to its high molecular weight (~863 Da), extreme lipophilicity (log P ~19.4), and crystalline nature. The MicroActive formulation addresses this via solubilization with β-cyclodextrin complexation and polymer-based controlled release. Active compound: Ubiquinone (oxidized form of CoQ10), a fat-soluble, vitamin-like benzoquinone with a 10-unit isoprenoid side chain. No significant macronutrients (protein, fat, carbohydrate, fiber) are present in meaningful amounts per serving. No vitamins or minerals are added unless specified by a particular manufacturer's formulation. CoQ10 functions endogenously as an electron carrier in the mitochondrial electron transport chain (Complex I → Complex III) and as a lipid-soluble antioxidant in cell membranes and lipoproteins. Endogenous synthesis declines with age (peak production ~age 20, with notable decline after age 40). Plasma CoQ10 reference range is approximately 0.4–1.9 µg/mL; supplementation at 100–200 mg/day typically raises plasma levels to 2–4 µg/mL. CoQ10 is transported primarily in LDL cholesterol in circulation. Note: Ubiquinone must be reduced to ubiquinol (QH2) in vivo to exert antioxidant function; this reduction occurs readily in healthy individuals but may be less efficient in elderly or metabolically compromised populations.

Preparation & Dosage

No clinically studied dosage ranges are documented for MicroActive CoQ10 in any form. The research indicates that standardization is not specified in studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not specified in research dossier

Safety & Interactions

CoQ10 in ubiquinone form, including MicroActive formulations, is generally well tolerated; the most commonly reported side effects are mild gastrointestinal complaints such as nausea, diarrhea, and stomach upset, typically at doses above 300 mg/day. CoQ10 can reduce the anticoagulant efficacy of warfarin (vitamin K antagonist) by structural similarity to vitamin K, requiring INR monitoring if co-administered. It may also lower blood pressure additively when combined with antihypertensive drugs, and may partially counteract the LDL-lowering effects of statin therapy, though it is often co-prescribed with statins to replenish statin-induced CoQ10 depletion. Safety data during pregnancy and lactation are insufficient to establish a clear risk profile, so use is generally discouraged unless directed by a physician.